Moderna updates EUA timeline for pediatric COVID-19 vaccines
Moderna yesterday announced an updated timeline for its COVID-19 vaccine for children. According to Moderna, the Food and Drug Administration last week notified the drug maker that it may not complete its assessment of the company’s EUA request for children age 12 to 17 before January 2022. The delay is to evaluate recent international analyses of the risk of myocarditis after vaccination. As a result, Moderna said it will also delay requesting an EUA for its 50-microgram-dose version of the vaccine for 6- to 11-year-olds.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…